JPH03504644A - 架橋抗体とその製法 - Google Patents
架橋抗体とその製法Info
- Publication number
- JPH03504644A JPH03504644A JP2503004A JP50300490A JPH03504644A JP H03504644 A JPH03504644 A JP H03504644A JP 2503004 A JP2503004 A JP 2503004A JP 50300490 A JP50300490 A JP 50300490A JP H03504644 A JPH03504644 A JP H03504644A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cross
- reporter
- zygote
- crosslink
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6877—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the antibody being an immunoglobulin containing regions, domains or residues from different species
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
- A61K51/1087—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin the immunoglobulin comprises domains from different animal species, e.g. chimeric immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (21)
- (1)1個もしくは2個以上のレポーターまたはエフェクター基を含む少なくと も1個の鎖間架橋を有する標識抗体分子からなり、その架橋は抗体の抗原結合ド メインの外側に位置する1個または2個以上の架橋位置で各鎖に結合する架橋抗 体接合体。
- (2)架橋部位はアミノ酸残基の側鎖に存在するアミノ、スルフヒドリル、カル ボキシル、フェノールまたは他の芳香族もしくは異項環芳香族官能基である請求 項(1)記載の接合体。
- (3)架橋部位はシステイン残基の側鎖に存在するスルフヒドリル基である請求 項(2)記載の接合体。
- (4)システイン残基は蝶番領域における各重鎖中に存在する請求項(3)記載 の接合体。
- (5)システイン残基は蝶番領域に存在する唯一つのシステイン残基である請求 項(4)記載の接合体。
- (6)抗体は組換え抗体である請求項(1)〜(5)のいずれかに記載の接合体 。
- (7)抗体は抗体フラグメントである請求項(1)〜(6)のいずれかに記載の 接合体。
- (8)フラグメントはF(ab′)2フラグメントである請求項(7)記載の接 合体。
- (9)非ジスルフィド性鎖間架橋は同種または異種官能性架橋剤の残基である請 求項(1)〜(8)のいずれかに記載の接合体。
- (10)標識抗体分子は、レポーターまたはエフェクター基が結合している抗体 分子である請求項(1)〜(9)のいずれかに記載の接合体。
- (11)レポーターまたはエフェクター基は、放射性核種キレート化金属、蛍光 化合物、NMRもしくはESRで検出できる化合物、薬理学的物質、酵素または ホルモンである請求項(10)記載の接合体。
- (12)レポーターまたはエフェクター基は、放射性核種またはキレート化金属 である請求項(11)記載の接合体。
- (13)放射性核種は放射性ヨウ素である請求項(12)記載の接合体。
- (14)キレート化金属は、配位数2から8までの二価または三価陽性金属と多 座キレート剤のキレートである請求項(12)記載の接合体。
- (15)多産キレート剤は、非環式もしくは環式ポリアミン、ポリエーテル、ポ リアミド、ポルフィリンまたは炭素環式誘導体である請求項(14)記載の接合 体。
- (16)非環式ポリアミンはポリアミノカルボン酸である請求項(15)記載の 接合体。
- (17)環式ポリアミンは環式トリアザまたはテトラアザ誘導体である請求項( 15)記載の接合体。
- (18)1個または2個以上のレポーターまたはエフェクター基を含有する鎖間 架橋を有する抗体分子であって、その架橋は抗体の抗原結合ドメインの外側に位 置する1個または2個以上の架橋部位で各鎖に結合している抗体と、1種または 2種以上の医薬的に許容される担体または賦形剤からなる医薬組成物。
- (19)1個または2個以上のレポーターまたはエフェクター基を含有する鎖間 架橋を有する抗体分子であって、その架橋は抗体の抗原結合ドメインの外側に位 置する1個または2個以上の架橋部位で各鎖に結合している抗体接合体を製造す るにあたり、架橋剤を抗体と反応させる方法。
- (20)抗体は架橋剤に対して過剰濃度で存在させる請求項(19)記載の方法 。
- (21)1個または2個以上のレポーターまたはエフェクター基を含有する鎖間 架橋を有する抗体分子からなり、その架橋は抗体の抗原結合ドメインの外側に位 置する1個または2個以上の架橋部位で各鎖に結合している、ヒトまたは動物対 象の処置または診断方法に使用するための抗体接合体。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8903022.5 | 1989-02-10 | ||
GB898903022A GB8903022D0 (en) | 1989-02-10 | 1989-02-10 | Chemical compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH03504644A true JPH03504644A (ja) | 1991-10-09 |
JP2975676B2 JP2975676B2 (ja) | 1999-11-10 |
Family
ID=10651472
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2503004A Expired - Lifetime JP2975676B2 (ja) | 1989-02-10 | 1990-02-12 | 架橋抗体とその製法 |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP0384624B1 (ja) |
JP (1) | JP2975676B2 (ja) |
KR (1) | KR910700075A (ja) |
AT (1) | ATE123952T1 (ja) |
AU (1) | AU632536B2 (ja) |
CA (1) | CA2026312A1 (ja) |
DE (1) | DE69020182T2 (ja) |
FI (2) | FI904974A0 (ja) |
GB (2) | GB8903022D0 (ja) |
HU (1) | HUT56288A (ja) |
IE (1) | IE67320B1 (ja) |
IL (1) | IL93361A0 (ja) |
NO (1) | NO904367L (ja) |
NZ (1) | NZ232490A (ja) |
WO (1) | WO1990009195A1 (ja) |
ZA (1) | ZA90983B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012207027A (ja) * | 2004-11-22 | 2012-10-25 | Ge Healthcare As | 造影剤 |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5194594A (en) * | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
GB9112536D0 (en) * | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
US6764681B2 (en) | 1991-10-07 | 2004-07-20 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
DE19911329A1 (de) * | 1998-03-27 | 2000-09-21 | Benes Ivan Friedrich | Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung |
GB9812545D0 (en) | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
NZ552959A (en) | 1998-11-27 | 2008-06-30 | Darwin Discovery Ltd | Compositions and methods for increasing bone mineralization |
EP1419236A4 (en) | 2001-07-24 | 2005-08-03 | Biogen Idec Inc | METHODS OF TREATING OR PREVENTING SCLEROSIS BY USE OF CD2-BINDING AGENTS |
GB0124317D0 (en) | 2001-10-10 | 2001-11-28 | Celltech R&D Ltd | Biological products |
JP2005181192A (ja) * | 2003-12-22 | 2005-07-07 | Tacmina Corp | 残留塩素濃度測定方法 |
CA2565259A1 (en) | 2004-05-07 | 2005-12-08 | Astellas Us Llc | Soluble lfa-3 polypeptide for treating viral disorders |
DE102005034950A1 (de) | 2005-07-22 | 2007-02-01 | Tesa Ag | Abroller für die Herstellung eines Klebebandschlauchs |
ATE485517T1 (de) | 2006-03-22 | 2010-11-15 | Viral Logic Systems Technology | Verfahren zur identifizierung von polypeptid- targets |
US8377448B2 (en) | 2006-05-15 | 2013-02-19 | The Board Of Trustees Of The Leland Standford Junior University | CD47 related compositions and methods for treating immunological diseases and disorders |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4751286A (en) * | 1985-11-19 | 1988-06-14 | The Johns Hopkins University | Protein label and drug delivery system |
GB8603537D0 (en) * | 1986-02-13 | 1986-03-19 | Parker D | Conjugate compound |
GB8720833D0 (en) * | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
-
1989
- 1989-02-10 GB GB898903022A patent/GB8903022D0/en active Pending
-
1990
- 1990-02-09 ZA ZA90983A patent/ZA90983B/xx unknown
- 1990-02-12 EP EP90301441A patent/EP0384624B1/en not_active Expired - Lifetime
- 1990-02-12 WO PCT/GB1990/000213 patent/WO1990009195A1/en active Application Filing
- 1990-02-12 IL IL93361A patent/IL93361A0/xx unknown
- 1990-02-12 IE IE49490A patent/IE67320B1/en not_active IP Right Cessation
- 1990-02-12 AT AT90301441T patent/ATE123952T1/de not_active IP Right Cessation
- 1990-02-12 HU HU901641A patent/HUT56288A/hu unknown
- 1990-02-12 JP JP2503004A patent/JP2975676B2/ja not_active Expired - Lifetime
- 1990-02-12 CA CA002026312A patent/CA2026312A1/en not_active Abandoned
- 1990-02-12 DE DE69020182T patent/DE69020182T2/de not_active Expired - Lifetime
- 1990-02-12 AU AU50475/90A patent/AU632536B2/en not_active Ceased
- 1990-02-12 KR KR1019900702231A patent/KR910700075A/ko not_active Application Discontinuation
- 1990-02-12 NZ NZ232490A patent/NZ232490A/en unknown
- 1990-10-09 FI FI904974A patent/FI904974A0/fi not_active Application Discontinuation
- 1990-10-09 GB GB9021894A patent/GB2237020B/en not_active Revoked
- 1990-10-09 NO NO90904367A patent/NO904367L/no unknown
- 1990-10-09 FI FI904975A patent/FI904975A0/fi not_active Application Discontinuation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012207027A (ja) * | 2004-11-22 | 2012-10-25 | Ge Healthcare As | 造影剤 |
Also Published As
Publication number | Publication date |
---|---|
GB8903022D0 (en) | 1989-03-30 |
GB2237020B (en) | 1993-04-14 |
IE900494L (en) | 1990-08-10 |
EP0384624B1 (en) | 1995-06-21 |
FI904975A0 (fi) | 1990-10-09 |
FI904974A0 (fi) | 1990-10-09 |
NO904367L (no) | 1990-12-06 |
WO1990009195A1 (en) | 1990-08-23 |
NO904367D0 (no) | 1990-10-09 |
CA2026312A1 (en) | 1990-08-11 |
NZ232490A (en) | 1992-09-25 |
EP0384624A2 (en) | 1990-08-29 |
KR910700075A (ko) | 1991-03-13 |
DE69020182D1 (de) | 1995-07-27 |
IE67320B1 (en) | 1996-03-20 |
EP0384624A3 (en) | 1990-11-14 |
ATE123952T1 (de) | 1995-07-15 |
IL93361A0 (en) | 1990-11-29 |
AU632536B2 (en) | 1993-01-07 |
AU5047590A (en) | 1990-09-05 |
HUT56288A (en) | 1991-08-28 |
ZA90983B (en) | 1991-10-30 |
GB2237020A (en) | 1991-04-24 |
JP2975676B2 (ja) | 1999-11-10 |
DE69020182T2 (de) | 1995-11-30 |
HU901641D0 (en) | 1991-03-28 |
GB9021894D0 (en) | 1990-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2975677B2 (ja) | 架橋抗体およびその製造方法 | |
JP3373849B2 (ja) | 3価および4価の単一特異性抗原結合性タンパク質 | |
US6511663B1 (en) | Tri- and tetra-valent monospecific antigen-binding proteins | |
EP0397213A1 (en) | Radiolabeled antibody fragments | |
EP0455268A1 (en) | Biologically useful conjugates | |
US6509451B1 (en) | Cross-linked antibodies and processes for their preparation | |
JPH03504644A (ja) | 架橋抗体とその製法 | |
JP2001506990A (ja) | 一価の(monovalent)抗体フラグメント | |
US5714149A (en) | Crosslinked antibodies and processes for their preparation | |
EP0569531B1 (en) | Stabilized antibody fragments | |
IE921898A1 (en) | Tri- and tetravalent mono specific antigen binding proteins | |
Schmitz-Dräger et al. | Monoclonal antibodies and renal cell carcinoma—current possibilities and future options | |
JPH07126187A (ja) | 抗癌剤 | |
JPH0853499A (ja) | キメラ抗体Fab断片のオリゴマー体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080903 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080903 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090903 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100903 Year of fee payment: 11 |
|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100903 Year of fee payment: 11 |